Literature DB >> 27753009

Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer.

Xiaodan Meng1, Volkmar Müller2, Karin Milde-Langosch2, Fabian Trillsch2, Klaus Pantel1, Heidi Schwarzenbach3.   

Abstract

In the present study, we investigated whether circulating cell-free microRNAs serve as potential biomarkers in epithelial ovarian cancer (EOC) patients. Circulating miR-373, miR-200a, miR-200b and miR-200c were quantified in a cohort of 60 EOC patients, 20 patients with benign ovarian diseases and 32 healthy women using quantitative TaqMan MicroRNA assays. The serum concentrations of cell-free miR-373, miR-200a, miR-200b and miR-200c were significantly higher in EOC patients than in healthy women (p = 0.0001). With a sensitivity of 83 % and a specificity of 100 %, the combination of miR-200a, miR-200b and miR-200c could differ between malignant and benign ovarian tumors (p = 0.0001). Elevated levels of these cell-free microRNAs could be detected in FIGO I-II and FIGO III-IV stages, grading G1-2 and G3 and lymph node-negative and -positive EOC. In conclusion, the increased serum levels of this microRNA panel have diagnostic value for distinguishing healthy controls and benign tumors from EOC.

Entities:  

Keywords:  Cell-free miRNAs; FIGO stage; Metastases; Tumor progression

Mesh:

Substances:

Year:  2016        PMID: 27753009     DOI: 10.1007/978-3-319-42044-8_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  19 in total

Review 1.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

Review 2.  Extracellular vesicles in immunomodulation and tumor progression.

Authors:  Carolyn Marar; Bartholomew Starich; Denis Wirtz
Journal:  Nat Immunol       Date:  2021-03-22       Impact factor: 31.250

3.  Differential distribution of tumor-associated macrophages and Treg/Th17 cells in the progression of malignant and benign epithelial ovarian tumors.

Authors:  Qinyi Zhu; Xiaoli Wu; Xipeng Wang
Journal:  Oncol Lett       Date:  2016-11-23       Impact factor: 2.967

4.  Adipose-Derived Stem Cells Suppress Inflammation Induced by IL-1β through Down-Regulation of P2X7R Mediated by miR-373 in Chondrocytes of Osteoarthritis.

Authors:  Rilong Jin; Miaoda Shen; Liedao Yu; Xuanwei Wang; Xiangjin Lin
Journal:  Mol Cells       Date:  2017-03-27       Impact factor: 5.034

Review 5.  Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.

Authors:  Alka Singh; Sameer Gupta; Manisha Sachan
Journal:  Front Cell Dev Biol       Date:  2019-09-19

6.  The Accuracy of Single MicroRNAs in Peripheral Blood to Diagnose Ovarian Cancer: An Updated Meta-Analysis.

Authors:  Yubao Cui; Shanchao Hong; Xuming Zhu
Journal:  Dis Markers       Date:  2020-01-14       Impact factor: 3.434

7.  MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer.

Authors:  Jun Xiong; Xiaoju He; Yuanyuan Xu; Wei Zhang; Fen Fu
Journal:  J Ovarian Res       Date:  2021-06-02       Impact factor: 4.234

8.  Oncogenic Role of miR-200c-3p in High-Grade Serous Ovarian Cancer Progression via Targeting the 3'-Untranslated Region of DLC1.

Authors:  Sheril June Ankasha; Mohamad Nasir Shafiee; Norhazlina Abdul Wahab; Raja Affendi Raja Ali; Norfilza Mohd Mokhtar
Journal:  Int J Environ Res Public Health       Date:  2021-05-27       Impact factor: 3.390

Review 9.  Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer.

Authors:  Severyn Ferneza; Markiyan Fetsych; Roman Shuliak; Halyna Makukh; Natalia Volodko; Roman Yarema; Taras Fetsych
Journal:  Ecancermedicalscience       Date:  2021-06-14

10.  Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network.

Authors:  Xin Wang; Lei Han; Ling Zhou; Li Wang; Lan-Mei Zhang
Journal:  Oncol Rep       Date:  2018-09-13       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.